Increased MTHFD2 expression is associated with poor prognosis in breast cancer.
作者： Feng Liu , Yang Liu , Chuan He , Li Tao , Xiaoguang He
DOI: 10.1007/S13277-014-2111-X
关键词:
摘要: The aim of this study was to investigate the expression levels methylenetetrahydrofolate dehydrogenase (NADP + -dependent) 2 (MTHFD2) and associated clinical implications in breast cancer. MTHFD2 measured by Western blot immunohistochemistry 698 tissue sections taken from cancer patients. relationship between expression, clinicopathological parameters, prognosis subsequently determined. In comparison with para-carcinoma specimens, an enhanced observed specimens (P < 0.05). total, 41.12 % (287/698) had high MTHFD2. After universal Spearman regression correlation analyses, found correlate tumor size, histological grade, lymph node metastasis, distant metastases = 0.001, 0.002, respectively). Furthermore, patients MTHFD2-expressing tumors a significantly poorer than those no or low expression. 0.002). Using Cox test, identified as independent prognostic factor 0.001). differentially expressed tissue. Therefore, protein may be potential therapeutic target for future treatments.
springer.com
sci-hub.se 参考文章(20)
Muaiad Kittaneh, Alberto J. Montero, Stefan Glück, Molecular profiling for breast cancer: a comprehensive review. Biomarkers in Cancer. ,vol. 5, pp. 61- 70 ,(2013) , 10.4137/BIC.S9455
Laura Lehtinen, Kirsi Ketola, Rami Mäkelä, John-Patrick Mpindi, Miro Viitala, Olli Kallioniemi, Kristiina Iljin, High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion Oncotarget. ,vol. 4, pp. 48- 63 ,(2013) , 10.18632/ONCOTARGET.756
Maruyama Kazuo, Sugano Sumio, Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides. Gene. ,vol. 138, pp. 171- 174 ,(1994) , 10.1016/0378-1119(94)90802-8
Elvin Blanco, Mauro Ferrari, Emerging nanotherapeutic strategies in breast cancer The Breast. ,vol. 23, pp. 10- 18 ,(2014) , 10.1016/J.BREAST.2013.10.006
John S Meyer, , Consuelo Alvarez, Clara Milikowski, Neal Olson, Irma Russo, Jose Russo, Andrew Glass, Barbara A Zehnbauer, Karen Lister, Reza Parwaresch, Breast carcinoma malignancy grading by Bloom–Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index Modern Pathology. ,vol. 18, pp. 1067- 1078 ,(2005) , 10.1038/MODPATHOL.3800388
Cai-gang Liu, Ying Lu, Bin-bin Wang, Yan-jun Zhang, Rui-shan Zhang, Yang Lu, Bo Chen, Huimian Xu, Feng Jin, Ping Lu, Clinical implications of stem cell gene Oct-4 expression in breast cancer. Annals of Surgery. ,vol. 253, pp. 1165- 1171 ,(2011) , 10.1097/SLA.0B013E318214C54E
Asta Försti, Qianren Jin, Andrea Altieri, Robert Johansson, Kerstin Wagner, Kerstin Enquist, Ewa Grzybowska, Jolanta Pamula, Wioletta Pekala, Göran Hallmans, Per Lenner, Kari Hemminki, Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. Breast Cancer Research and Treatment. ,vol. 101, pp. 83- 93 ,(2007) , 10.1007/S10549-006-9265-1
Gayathri Anandappa, Nicholas C. Turner, Targeting receptor tyrosine kinases in HER2-negative breast cancer. Current Opinion in Oncology. ,vol. 25, pp. 594- 601 ,(2013) , 10.1097/CCO.0000000000000021
Dongyang Xu, Hong Xu, Ying Ren, Caigang Liu, Xuemei Wang, Hao Zhang, Ping Lu, Cancer Stem Cell-Related Gene Periostin: A Novel Prognostic Marker for Breast Cancer PLoS ONE. ,vol. 7, pp. e46670- ,(2012) , 10.1371/JOURNAL.PONE.0046670
S. Duygu Selcuklu, Mark T. A. Donoghue, Kristina Rehmet, Matheus de Souza Gomes, Antoine Fort, Prasad Kovvuru, Mohan K. Muniyappa, Michael J. Kerin, Anton J. Enright, Charles Spillane, MicroRNA-9 Inhibition of Cell Proliferation and Identification of Novel miR-9 Targets by Transcriptome Profiling in Breast Cancer Cells Journal of Biological Chemistry. ,vol. 287, pp. 29516- 29528 ,(2012) , 10.1074/JBC.M111.335943